Cindy Perettie

Executive Vice President and Global Head of Kite, Gilead Sciences

Search every verified Cindy Perettie interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Cindy Perettie, Executive Vice President and Global Head of Kite Pharma, discussed the company's cell therapy pipeline and launch preparations in a January 2026 podcast appearance. She stated that Kite has two marketed products, Yescarta and Tecartus, and is preparing for a U.S. launch of its multiple myeloma therapy in the second half of the year, developed in collaboration with Arcellx. Perettie described the partnership as strong, noting that Arcellx contributed innovation with a differentiated safety and efficacy profile, while Kite provides expertise in scaling therapies. She also mentioned that Kite shared data at the American Society of Hematology meeting on a next-generation lymphoma product intended to replace Yescarta and Tecartus, and that a head-to-head trial of this product, Kite 753, against Yescarta has begun. Perettie emphasized that cell therapies are currently delivered through authorized treatment centers with independent accreditations, though she suggested a future where delivery could be more widespread in community practices. In a 2019 podcast appearance as CEO of Foundation Medicine, Perettie discussed the company's focus on comprehensive genomic profiling for cancer patients. She noted that among the approximately 1.5 million patients diagnosed annually with advanced cancer, only 15 to 20 percent receive comprehensive genomic profiling, while another 25 percent receive single-marker hotspot testing, leaving 60 percent without any genomic testing. She highlighted the importance of preserving tissue from biopsies, particularly for lung cancer patients, and cited the company's over 57 collaborations with biopharma companies to make genomic data meaningful for clinical decision-making.